次脑叶切除治疗胶质母细胞瘤的疗效与安全性:倾向评分加权研究
该回顾性单中心研究纳入989例IDH野生型胶质母细胞瘤患者,其中331例符合次脑叶切除标准并完成术后放化疗。经倾向评分匹配和逆概率加权分析,次脑叶切除较对比增强肿瘤切除显著延长总生存期(25.6 vs 18.1个月)和无进展生存期(17.0 vs 12.0个月),且未增加功能风险。
要点
- 次脑叶切除显著改善IDH野生型胶质母细胞瘤的总生存和无进展生存。
- 功能评估显示次脑叶切除未额外损害生活质量、体能或语言功能。
- TERT启动子突变或MGMT启动子甲基化患者生存获益更明显。
核心结论
- 次脑叶切除是功能优化的超最大范围切除策略,对胶质母细胞瘤安全且显著延长生存。
研究设计与样本
- 回顾性单中心研究,分析989例IDH野生型胶质母细胞瘤,401例符合次脑叶切除解剖标准,最终纳入331例。
- 采用倾向评分匹配和逆概率加权减少混杂偏倚,用Kaplan-Meier和Cox模型评估生存。
主要发现
- 次脑叶切除组中位总生存25.6个月,对比增强肿瘤切除组18.1个月(p < 0.001)。
- 次脑叶切除组中位无进展生存17.0个月,对比增强肿瘤切除组12.0个月(p < 0.001)。
- 功能评估未发现生活质量、体能或语言功能的额外风险。
- RANO 1类患者中次脑叶切除同样显著改善总生存和无进展生存。
- TERTp突变或MGMTp甲基化患者生存获益更大,最大安全水肿切除是改善结局的关键因素。
临床怎么用
- 对符合解剖标准的IDH野生型胶质母细胞瘤,可考虑次脑叶切除以安全扩大切除范围并改善生存。
- 术前结合功能定位确定 lobe-specific 解剖边界,实现最大安全水肿切除。
- 术后功能评估应关注生活质量、体能和语言功能,次脑叶切除未显示额外风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Sublobectomy is a modified surgical paradigm based on anatomical lobectomy, incorporating functional boundaries to extend resection safely, particularly for glioblastoma, a highly aggressive brain tumor. This study aimed to evaluate the efficacy and safety of sublobectomy and its prognostic value within the Response Assessment in Neuro-Oncology (RANO) categories for extent of resection. METHODS: Building on their clinical practice, the authors established a sublobectomy standard defined by lobe-specific anatomical boundaries complemented by functional mapping limits and applied it across the frontal, temporal, parietal, and occipital lobes. In this retrospective single-center study, 989 IDH-wildtype glioblastoma cases were analyzed, and 401 met the anatomical criteria for sublobectomy. After excluding cases with residual contrast-enhancing (CE) tumor or incomplete postoperative chemoradiotherapy, 331 cases were included. Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) were used to minimize confounding biases. Survival outcomes were assessed using Kaplan-Meier survival analysis and Cox proportional hazards models, while functional outcomes were evaluated using Karnofsky Performance Status, Boston Diagnostic Aphasia Examination, and Eastern Cooperative Oncology Group scores. RESULTS: Sublobectomy significantly improved overall survival (OS) and progression-free survival (PFS) compared to CE tumor resection (median OS: 25.6 vs 18.1 months [p < 0.001], median PFS: 17.0 vs 12.0 months [p < 0.001]). These findings remained consistent after IPTW and PSM analyses. Functional assessments showed no additional risks to quality of life, physical performance, or language function. In RANO class 1 patients, sublobectomy also significantly improved OS and PFS. Subgroup analyses revealed greater survival benefits in patients with TERTp mutations or MGMTp methylation. Maximal safe edema resection emerged as a key factor for improved outcomes. CONCLUSIONS: Sublobectomy is a functionally optimized supramaximal resection strategy with favorable safety and significant survival benefits for glioblastoma patients.
引用
- Luo C, Song Y, Zhu G, et al. The efficacy and safety of sublobectomy for glioblastoma: a propensity score-weighted study. J Neurosurg. 2026. PMID: 42030559. doi:10.3171/2025.12.JNS251341
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。